Overview

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure control without increasing adverse effects. This trial is designed to investigate the efficacy and safety of GMRx2 in participants with high blood pressure compared to dual combinations.
Phase:
Phase 3
Details
Lead Sponsor:
George Medicines PTY Limited
Treatments:
Amlodipine
Indapamide
Telmisartan